Clinical Trial Update: Evaluating Different Doses of Orelabrutinib in MCL [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating different doses of orelabrutinib in Mantle Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: InnoCare Pharma Inc. | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN